877-638-7251 Menu

Company overview

Neural Analytics is building 21st century screening, diagnostic, monitoring and medical device systems to reshape how brain health is managed.

In 2013, Neural Analytics founders Leo Petrossian, Robert Hamilton and Dan Hanchey were introduced to leading-edge technology in the UCLA Department of Neurosurgery. After exclusively licensing the technology from UCLA, the team immediately began research and development efforts sponsored by National Science Foundation (NSF) and National Institutes of Health (NIH) funding. Neural Analytics has developed leading brain health technology and is in the process of commercializing products for the near future. The company is based in Los Angeles, CA.

“We are rapidly developing technologies to improve brain health, improve patient lives and prevent unnecessary tragedies.” Leo Petrossian, Chief Executive Officer

Neural Analytics Team

Leo Petrossian, PHD

Co-Founder & Chief Executive Officer

Leo is co-founder and CEO of Neural Analytics. Prior to Neural Analytics, Leo obtained his MBA from UCLA Anderson and his PhD in biomolecular nanotechnology as an NSF IGERT fellow.

Robert Hamilton, PHD

Co-Founder & Chief Science Officer

Robert Hamilton, Ph.D. Co-founder and Chief Scientific Officer. Dr. Hamilton completed his Ph.D. in Biomedical Engineering at UCLA focused on the analysis of cerebral dynamics. At Neural Analytics Dr. Hamilton leads scientific development and strategic direction for the core technology.

Kevin Rubey

Chief Operating Officer

Kevin has been involved with Neural Analytics since April, 2016. His career has been focused on medical devices and defense related products and markets. He has experience with numerous medical device start-up companies, three IPO’s, multinational conglomerates, multiple acquisitions and divestitures, holds two privately held companies and has built world wide enterprises.

Javad Seyedzadeh

Head of Quality and Regulatory Affairs

Javad brings to Neural Analytics 30 years of experience improving quality systems, process efficiency, regulatory compliance, product cost and organizational design, by establishing operational excellence through teamwork, lean six sigma and customer driven quality interaction. Javad served as Global Senior Vice President of Quality Assurance and Regulatory Affairs at Gambro AB. He has extensive knowledge and experience from the QA/RA arena, having operated globally for many years within the medical and diagnostic industry. Prior to joining Gambro, he was the Senior Vice President of Siemens Medical Solutions Diagnostics Division, where he was responsible for global Quality Assurance, Regulatory Affairs, Quality Systems, Health Environment and Safety, Reimbursement and Government Affairs, Medical and Clinical Affairs, and Biostatistics. He also served as a member of the Siemens Medical Solutions Diagnostics Management Group. Prior to joining Siemens, Mr. Seyedzadeh led the Quality and Regulatory functions at Bayer Diagnostics and Toshiba, where he helped create an innovative, worldwide quality management system-encompassing more than fifteen sites in forty-four countries-that made the division an industry leader. Mr. Seyedzadeh serves as a Director of JS Genetics, Inc. He is an advisor to the Food and Drug Administration's Office of Diagnostics Devices Evaluation and sits on the ADVAMED advisory group.

Neil A. Martin, MD, FAANS

Chief Medical Officer

Dr. Martin serves as a Professor, and the W. Eugene Stern Chairman of Neurosurgery at the UCLA Ronald Reagan Hospital in Los Angeles, California. His additional roles include Co-Director of the UCLA Stroke Center, Medical Director of the Cerebral Blood Flow and TCD Laboratory, and Director of the Aneurysm and AVM program. Dr. Martin specializes in the research and treatment of brain injury and neurovascular disorders, including arteriovenous malformation, aneurysm and stroke. Over the past twenty years, Dr. Martin and his team have collaborated with colleagues in interventional neuroradiology and stereotactic radiosurgery to treat more than 5,000 patients with central nervous system vascular disorders including aneurysms, arteriovenous malformations, and carotid and intracranial atherosclerosis.

Henry Hewes

VP of Sales & Global Marketing

Henry Hewes is Vice President of Global Marketing for Neural Analytics. He comes to the team with over 15 years of commercial experience. Prior to Neural Analytics Henry held roles of increasing executive leadership responsibilities at Medtronic including Director of Global Marketing for the Acute Ischemic Stroke Neurovascular Business. Henry earned is Masters in Marketing and Corporate Strategy from The Carlson School of Management at the University of Minnesota.

Dan Hanchey

Co-founder   VP Software Engineering

Dan completed his MBA at UCLA Anderson in 2013, Dan cofounded Neural Analytics and now heads product development. Prior to Neural Analytics, Dan was Senior Software Architect for a leading CAD/CAM application.

Aaron Green

VP of Administration

Aaron joined Neural Analytics in 2014 and heads team culture and administration. He obtained his PhD in computational chemistry as an NSF Fellow in 2013.

Jay Yonemoto

VP of Engineering

Jay is VP of Engineering and is responsible for bringing products to market at Neural Analytics. He joined the company in 2015 and has over 25 years of medical device product development experience.

Board Members

Roy Doumani

Board Chairman

Leo is co-founder and CEO of Neural Analytics. Prior to Neural Analytics, Leo obtained his MBA from UCLA Anderson and his PhD in biomolecular nanotechnology as an NSF IGERT fellow.